"Salvage therapy" trang 1 - tải miễn phí từ tailieunhanh
Patterns of recurrence after surgery and efficacy of salvage therapy after recurrence in patients with thoracic esophageal squamous cell carcinoma

Patterns of recurrence after surgery and efficacy of salvage therapy after recurrence in patients with thoracic esophageal squamous cell carcinoma
9    76    0
ElectroMotive drug administration (EMDA) of Mitomycin C as first-line salvage therapy in high risk “BCG failure” non muscle invasive bladder cancer: 3 years follow-up outcomes

ElectroMotive drug administration (EMDA) of Mitomycin C as first-line salvage therapy in high risk “BCG failure” non muscle invasive bladder cancer: 3 years follow-up outcomes
9    75    1
Retrospective observational study of salvage line ramucirumab monotherapy for patients with advanced gastric cancer

Retrospective observational study of salvage line ramucirumab monotherapy for patients with advanced gastric cancer
9    76    0
A phase II randomized placebo-controlled double-blind study of salvage radiation therapy plus placebo versus SRT plus enzalutamide with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA)

A phase II randomized placebo-controlled double-blind study of salvage radiation therapy plus placebo versus SRT plus enzalutamide with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA)
10    80    1
Clinical response and pharmacokinetics of bendamustine as a component of salvage R-B(O)AD therapy for the treatment of primary central nervous system lymphoma (PCNSL)

Clinical response and pharmacokinetics of bendamustine as a component of salvage R-B(O)AD therapy for the treatment of primary central nervous system lymphoma (PCNSL)
10    51    1
Intracranial efficacy and safety of furmonertinib 160mg with or without anti-angiogenic agent in advanced NSCLC patients with BM/LM as salvage therapy

Intracranial efficacy and safety of furmonertinib 160mg with or without anti-angiogenic agent in advanced NSCLC patients with BM/LM as salvage therapy
11    5    1
Surveillance or metastasis-directed Therapy for OligoMetastatic Prostate cancer recurrence (STOMP): Study protocol for a randomized phase II trial

Surveillance or metastasis-directed Therapy for OligoMetastatic Prostate cancer recurrence (STOMP): Study protocol for a randomized phase II trial
6    32    1
Study protocol for prospective multi-institutional phase III trial of standard of care therapy with or without stereotactic ablative radiation therapy for recurrent ovarian cancer (SABR-ROC)

Study protocol for prospective multi-institutional phase III trial of standard of care therapy with or without stereotactic ablative radiation therapy for recurrent ovarian cancer (SABR-ROC)
7    3    1
Salvage chemoradiotherapy after primary chemotherapy for locally advanced pancreatic cancer: A single-institution retrospective analysis

Salvage chemoradiotherapy after primary chemotherapy for locally advanced pancreatic cancer: A single-institution retrospective analysis
10    50    1
Stereotactic body radiation therapy as a salvage treatment for single viable hepatocellular carcinoma at the site of incomplete transarterial chemoembolization: A retrospective analysis of 302 patients

Stereotactic body radiation therapy as a salvage treatment for single viable hepatocellular carcinoma at the site of incomplete transarterial chemoembolization: A retrospective analysis of 302 patients
10    20    1
Báo cáo khoa học:

Báo cáo khoa học: " Salvage radiotherapy for biochemical relapse after complete PSA response following radical prostatectomy: outcome and prognostic factors for patients who have never received hormonal therapy"
9    83    0
Báo cáo y học:

Báo cáo y học: "Multiple independent origins of a protease inhibitor resistance mutation in salvage therapy patients"
9    83    0
The salvage therapy in lung adenocarcinoma initially harbored susceptible EGFR mutation and acquired resistance occurred to the first-line gefitinib and second-line cytotoxic chemotherapy

The salvage therapy in lung adenocarcinoma initially harbored susceptible EGFR mutation and acquired resistance occurred to the first-line gefitinib and second-line cytotoxic chemotherapy
9    83    0
Long-term outcomes of the 2-week schedule of hypofractionated radiotherapy for recurrent hepatocellular carcinoma

Long-term outcomes of the 2-week schedule of hypofractionated radiotherapy for recurrent hepatocellular carcinoma
8    38    1
Management and treatment of relapsed or refractory Ph(−) B-precursor ALL: A webbased, double-blind survey of EU clinicians

Management and treatment of relapsed or refractory Ph(−) B-precursor ALL: A webbased, double-blind survey of EU clinicians
8    57    1
Survival outcomes including salvage therapy of adult head and neck para-meningeal rhabdomyosarcoma: A multicenter retrospective study from Japan

Survival outcomes including salvage therapy of adult head and neck para-meningeal rhabdomyosarcoma: A multicenter retrospective study from Japan
9    6    1
Salvage chemoradiation therapy for recurrence after radical surgery or palliative surgery in esophageal cancer patients: A prospective, multicenter clinical trial protocol

Salvage chemoradiation therapy for recurrence after radical surgery or palliative surgery in esophageal cancer patients: A prospective, multicenter clinical trial protocol
8    54    1